Abstract
Background
Objective
Methods
Results
Figures and Tables
Fig. 1
(A) A 10-year-old boy with alopecia universalis before and after 24 weeks of treatment. (B) A 23-year-old women with alopecia universalis before and after 24 weeks of treatment. (C) A 35-year-old man with alopecia universalis before and after 24 weeks of treatment. (D) A 16-year-old women with alopecia areata affecting more than 75% of hair loss before and after 24 weeks of treatment.
![ad-20-172-g001](/upload/SynapseData/ArticleImage/0140ad/ad-20-172-g001.jpg)
Fig. 2
Trough concentration of cyclosporine A in the responders and poor-responders. The mean trough concentration of cyclosporine A in the responders was 94.2 ng/ml (range: 22.1~162.1 ng/ml) and 101.2 ng/ml (range: 39.2~178.4 ng/ml) in the poor-responders. The responders displayed a lower mean trough concentration than did the poor-responders (p<0.05).
![ad-20-172-g002](/upload/SynapseData/ArticleImage/0140ad/ad-20-172-g002.jpg)
Fig. 3
Trough concentration of cyclosporine A in the patients with and without side effects. In the group with side effects, the mean concentration of cyclosporine A was 195.8 ng/ml (34.8~381.2 ng/ml). The mean concentration of cyclosporine A in the patients without side effects was 91.2 ng/ml (22.1~204.8 ng/ml). The difference of the trough concentration of cyclosporine A between these two groups was significant (p<0.05).
![ad-20-172-g003](/upload/SynapseData/ArticleImage/0140ad/ad-20-172-g003.jpg)
Table 1
Demographic data of 24 patients of the clinical responders
![ad-20-172-i001](/upload/SynapseData/ArticleImage/0140ad/ad-20-172-i001.jpg)
*Extent of AA: in accordance with the National Alopecia Areata Foundation guidelines: S0: no hair loss, S1: <25% hair loss, S2: 26~50%, S3: 51~75%, S4: 76~99%, Alopecia totalis (AT): total scalp hair loss, Alopecia universalis (AU): total scalp and body hair loss, Alopecia totalis/universalis (AT/AU): alopecia totalis with variable degrees of loss of body hair, †MTC: the mean trough concentration of cyclosporine A, ‡CsA: cyclosporin A, §MPDS: methylprednisone
Table 2
Demographic data of 10 patients of the clinical poor responders
![ad-20-172-i002](/upload/SynapseData/ArticleImage/0140ad/ad-20-172-i002.jpg)
*Extent of AA: in accordance with the guidelines of National Alopecia Areata Foundation guidelines: S0: no hair loss, S1: <25% hair loss, S2: 26~50%, S3:51~75%, S4: 76~99%, Alopecia totalis (AT): total scalp hair loss, Alopecia universalis (AU): total scalp and body hair loss, Alopecia totalis/universalis (AT/AU): alopecia totalis with variable degrees of loss of body hair, †MTC: the mean trough concentration of cyclosporine A, ‡CsA: cyclosporin A, §MPDS: methylprednisone
References
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)